First Time Loading...

Pulse Biosciences Inc
NASDAQ:PLSE

Watchlist Manager
Pulse Biosciences Inc Logo
Pulse Biosciences Inc
NASDAQ:PLSE
Watchlist
Price: 8.71 USD 3.69% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of PLSE.

Key Points:
PLSE Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

Finance and Clinical Updates from Earnings Call
2023-Q3 Earnings Call

Finance and Clinical Updates from Earnings Call

In a recent quarterly call, the company revealed a substantial reduction in non-GAAP total costs and expenses, lowering them from $16.8 million in the previous year to $9.2 million. This was attributed to headcount decreases and a significant inventory reserve in the prior year. R&D costs climbed by $2.3 million to support the advancement of Cardiology devices. The non-GAAP net loss was halved from $16.8 million to $8.5 million year-over-year, and they ended the quarter with $50.4 million in cash. Going forward, cash use is expected to be around $8 million in Q4 2023. The company also discussed their CellFX nsPFA technology's potential in treating atrial fibrillation and benign thyroid nodules, where it appears to be a superior alternative to existing therapies, hinting at significant market opportunities in both areas.

Financials

Balance Sheet Decomposition
Pulse Biosciences Inc

Current Assets 51.6m
Cash & Short-Term Investments 50.4m
Other Current Assets 1.2m
Non-Current Assets 14.3m
PP&E 9.1m
Intangibles 4.8m
Other Non-Current Assets 380k
Current Liabilities 5.4m
Accounts Payable 1.4m
Accrued Liabilities 4m
Non-Current Liabilities 8.4m
Other Non-Current Liabilities 8.4m
Efficiency

Earnings Waterfall
Pulse Biosciences Inc

Revenue
-10k USD
Cost of Revenue
-1.3m USD
Gross Profit
-1.3m USD
Operating Expenses
-38.5m USD
Operating Income
-39.8m USD
Other Expenses
310k USD
Net Income
-39.5m USD

Free Cash Flow Analysis
Pulse Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

PLSE Profitability Score
Profitability Due Diligence

Pulse Biosciences Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

47/100
Profitability
Score

Pulse Biosciences Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

PLSE Solvency Score
Solvency Due Diligence

Pulse Biosciences Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
63/100
Solvency
Score

Pulse Biosciences Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PLSE Price Targets Summary
Pulse Biosciences Inc

Wall Street analysts forecast PLSE stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PLSE is 5 USD .

Lowest
Price Target
Not Available
Average
Price Target
5 USD
43% Downside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

PLSE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

PLSE Price
Pulse Biosciences Inc

1M 1M
-12%
6M 6M
+116%
1Y 1Y
+247%
3Y 3Y
-61%
5Y 5Y
-50%
10Y 10Y
+109%
Annual Price Range
8.71
52w Low
2.48
52w High
12.84
Price Metrics
Average Annual Return -17.68%
Standard Deviation of Annual Returns 62.58%
Max Drawdown -97%
Shares Statistics
Market Capitalization 479m USD
Shares Outstanding 54 923 000
Percentage of Shares Shorted 14.83%

PLSE Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Pulse Biosciences Inc Logo
Pulse Biosciences Inc

Country

United States of America

Industry

Health Care

Market Cap

479m USD

Dividend Yield

0%

Description

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 142 full-time employees. The company went IPO on 2016-05-18. The firm provides CellFX System, which is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The CellFX System includes a multi-use handpiece and a suite of single-patient use treatment tips ranging from approximately 1.5 square millimeter (mm2) to 10 mm2, enabling treatment of a variety of lesion sizes and depths. The treatment tips wirelessly connect to the CellFX System when plugged into the handpiece, allowing for the use of automated treatment settings based on the treatment tip used. The firm has commercialized its CellFX System into the procedure market as its commercial market. Powered by the Company’s Nano-Pulse Stimulation (NPS) technology, the CellFX System delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue.

Contact

CALIFORNIA
Hayward
3957 Point Eden Way
+15109064600.0
http://www.pulsebiosciences.com/

IPO

2016-05-18

Employees

142

Officers

Executive Chairman
Mr. Robert W. Duggan
President & CEO
Mr. Kevin P. Danahy
CTO & Director
Mr. Darrin R. Uecker
Chief Strategy Officer
Mr. Mitchell E. Levinson
Chief Science Officer
Dr. Richard Nuccitelli Ph.D.
General Counsel & Corporate Secretary
Mr. Kenneth B. Stratton Esq., J.D.
Show More
Vice President of Human Resources
Ms. Patty Perla
Senior Vice President of Engineering
Mr. David Danitz
Chief Medical Officer
Dr. Gansevoort Dunnington M.D.
Chief Science Officer of Cardiac Surgery
Dr. Niv Ad M.D.
Show Less

See Also

Discover More